Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments.
Saved in:
| Title: | Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments. |
|---|---|
| Authors: | Muros-Le Rouzic E; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Heer Y; PricewaterhouseCoopers AG, Zürich, Switzerland., Yiu S; Roche Products Limited, Welwyn Garden City, UK., Tozzi V; PricewaterhouseCoopers AG, Zürich, Switzerland., Braune S; NeuroTransData GmbH, Neuburg an der Donau, Germany., van Hövell P; PricewaterhouseCoopers AG, Zürich, Switzerland., Bergmann A; NeuroTransData GmbH, Neuburg an der Donau, Germany., Bernasconi C; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Model F; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Craveiro L; F. Hoffmann-La Roche Ltd., Basel, Switzerland. |
| Corporate Authors: | NTD study group |
| Source: | Journal of central nervous system disease [J Cent Nerv Syst Dis] 2024 Sep 13; Vol. 16, pp. 11795735241260563. Date of Electronic Publication: 2024 Sep 13 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: SAGE Publications Country of Publication: United States NLM ID: 101595026 Publication Model: eCollection Cited Medium: Print ISSN: 1179-5735 (Print) Linking ISSN: 11795735 NLM ISO Abbreviation: J Cent Nerv Syst Dis Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1179-5735 |
|---|---|
| DOI: | 10.1177/11795735241260563 |
